Objetivo Brain cancers such as glioblastoma multiforme (GBM) are practically incurable due to their location, invasiveness and highly aggressive nature. The use of light-based treatments of GBM by activating tumor-localized photosensitizers, such as in photodynamic therapy (PDT) has been clinically evaluated, but with limited success. This is mainly due to the limited penetration of light into tissue and the efficient spread of tumor cells typically up to at least 2 cm from the resection margin. Moreover, the existing photon based treatments (photodynamic therapy) are highly invasive and usually require open-cranium surgery, due to the need for external light sources. In the Lumiblast project the photons are produced inside the tumor cells in the form of chemiluminescence avoiding the major limitation of using external light to treat solid, deep-sited and inaccessible tumors. The principle utilized in Lumiblast may also be relevant for cancers of other origins. Due to its nature Lumiblast is expected to act on individual cells, rather than the collective lesion; it could thus completely eliminate the hitherto incurable GBM. Each GBM cell is expected to become a small lamp providing the light required for the photosensitive agents to become activated, killing the tumour cells from the inside. Lumiblast requires a concerted interdisciplinary action. The project coordinator (Berg’s group, Oslo University Hospital, OUS) is world renowned in PDT and photomedicine, while the team from the University of Athens (Georgios Vougioukalakis’ group, UoA) is up and coming with high expertise in synthetic chemistry. The Polytechnic University of Valencia (Miguel Miranda’s group, UPV) team is headed by a world leader in Photochemistry, the University of Oslo partner (Hanne H. Tønnensen’s group, UiO) is specialized in pharmaceutical formulation, and Knight Scientific Ltd (KSL, CEO Jan Knight) is an SME with an impressive track record in ROS-activated luminescence. This 4.5-year project will establish the Lumiblast breakthrough technology by providing proof-of-concept in extracellular systems, GBM cell cultures and animal models, with the vision to advance Lumiblast to the clinic 5-6 years after the end of the proposed project. Ámbito científico medical and health sciencesclinical medicinesurgerynatural scienceschemical sciencesphysical chemistryphotochemistrymedical and health sciencesclinical medicineoncologysocial scienceseconomics and businessbusiness and managementemploymentnatural sciencesphysical sciencestheoretical physicsparticle physicsphotons Palabras clave photodynamic therapy photomedicine luminescence experimental therapeutics. mitochondrial medicine Programa(s) H2020-EU.1.2. - EXCELLENT SCIENCE - Future and Emerging Technologies (FET) Main Programme H2020-EU.1.2.1. - FET Open Tema(s) FETOPEN-RIA-2014-2015 - FET-Open research projects Convocatoria de propuestas H2020-FETOPEN-2014-2015 Consulte otros proyectos de esta convocatoria Convocatoria de subcontratación H2020-FETOPEN-2014-2015-RIA Régimen de financiación RIA - Research and Innovation action Coordinador OSLO UNIVERSITETSSYKEHUS HF Aportación neta de la UEn € 1 359 598,75 Dirección KIRKEVEIEN 166 TARNBYGGET 0450 Oslo Noruega Ver en el mapa Región Norge Oslo og Viken Oslo Tipo de actividad Higher or Secondary Education Establishments Enlaces Contactar con la organización Opens in new window Sitio web Opens in new window Participación en los programas de I+D de la UE Opens in new window Red de colaboración de HORIZON Opens in new window Coste total € 1 359 598,75 Participantes (4) Ordenar alfabéticamente Ordenar por aportación neta de la UE Ampliar todo Contraer todo ETHNIKO KAI KAPODISTRIAKO PANEPISTIMIO ATHINON Grecia Aportación neta de la UEn € 537 125,00 Dirección 6 CHRISTOU LADA STR 10561 Athina Ver en el mapa Región Αττική Aττική Κεντρικός Τομέας Αθηνών Tipo de actividad Higher or Secondary Education Establishments Enlaces Contactar con la organización Opens in new window Sitio web Opens in new window Participación en los programas de I+D de la UE Opens in new window Red de colaboración de HORIZON Opens in new window Coste total € 537 125,00 UNIVERSITAT POLITECNICA DE VALENCIA España Aportación neta de la UEn € 392 375,00 Dirección CAMINO DE VERA SN EDIFICIO 3A 46022 Valencia Ver en el mapa Región Este Comunitat Valenciana Valencia/València Tipo de actividad Higher or Secondary Education Establishments Enlaces Contactar con la organización Opens in new window Sitio web Opens in new window Participación en los programas de I+D de la UE Opens in new window Red de colaboración de HORIZON Opens in new window Coste total € 392 375,00 KNIGHT SCIENTIFIC LIMITED Reino Unido Aportación neta de la UEn € 367 500,00 Dirección 18 WESTERN COLLEGE ROAD PL4 7AG Plymouth Devon Ver en el mapa Pyme Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención. Sí Región South West (England) Devon Plymouth Tipo de actividad Private for-profit entities (excluding Higher or Secondary Education Establishments) Enlaces Contactar con la organización Opens in new window Participación en los programas de I+D de la UE Opens in new window Red de colaboración de HORIZON Opens in new window Coste total € 367 500,00 UNIVERSITETET I OSLO Noruega Aportación neta de la UEn € 374 776,25 Dirección PROBLEMVEIEN 5-7 0313 Oslo Ver en el mapa Región Norge Oslo og Viken Oslo Tipo de actividad Higher or Secondary Education Establishments Enlaces Contactar con la organización Opens in new window Sitio web Opens in new window Participación en los programas de I+D de la UE Opens in new window Red de colaboración de HORIZON Opens in new window Coste total € 374 776,25